نتایج جستجو برای: metronomic chemotherapy

تعداد نتایج: 114478  

2011
Jorge L. Soriano Noyde Batista Eduardo Santiesteban Mayté Lima Joaquín González Robin García Yohanka Zarza María V. López Myriam Rodríguez Jorge L. Loys Narciso Montejo Frank Aguirre Amparo Macías Ana M. Vázquez

The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and...

Amal Halim,

Background: The aim of this study was to investigate the efficacy and safety of metronomic capecitabine chemotherapy in pretreated elderly patients with advanced gastric carsonoma. Patients and Methods: Eligible patients were treated with capecitabine at a fixed dose of 1000mg daily until disease progression or toxicity. Endpoints were overall response rate, safety, progression-free survival...

Journal: :Anticancer research 2010
Sylvain Ladoire Jean Christophe Eymard Sylvie Zanetta Grégoire Mignot Etienne Martin Isabelle Kermarrec Eric Mourey Frédéric Michel Luc Cormier François Ghiringhelli

BACKGROUND There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting. PATIENTS AND METHODS From 2005 to 2010, patients with HRPC who failed at least doc...

2013
Erion Dobi Thierry Nguyen Christophe Borg Xavier Pivot Bernard Royer Stefano Kim

Background: Metronomic chemotherapy is based on antiangiogenic and immunologic mechanisms obtained by the administration of traditional cytotoxic drugs at lower concentration without rest periods. The low dosage induces fewer or no side effect compared to classic maximum tolerated dose administration (MTD). At present, no treatment related acute leukaemia was reported in cyclophosphamide-based ...

Journal: :Mathematical biosciences and engineering : MBE 2016
Ami B Shah Katarzyna A Rejniak Jana L Gevertz

While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell ...

2015
Cheryl A. London Heather L. Gardner Tamra Mathie Nicole Stingle Roberta Portela Michael L. Pennell Craig A. Clifford Mona P. Rosenberg David M. Vail Laurel E. Williams Kim L. Cronin Heather Wilson-Robles Antonella Borgatti Carolyn J. Henry Dennis B. Bailey Jennifer Locke Nicole C. Northrup Martin Crawford-Jakubiak Virginia L. Gill Mary K. Klein David M. Ruslander Doug H. Thamm Brenda Phillips Gerald Post

BACKGROUND We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy. METHODS AND FINDINGS This was a randomized, prospective clinical trial in which dogs with OSA free of gross me...

2017
Serena Mazzucchelli Michela Bellini Luisa Fiandra Marta Truffi Maria A. Rizzuto Luca Sorrentino Erika Longhi Manuela Nebuloni Davide Prosperi Fabio Corsi

Chemotherapeutic treatment of breast cancer is based on maximum tolerated dose (MTD) approach. However, advanced stage tumors are not effectively eradicated by MTD owing to suboptimal drug targeting, onset of therapeutic resistance and neoangiogenesis. In contrast, "metronomic" chemotherapy is based on frequent drug administrations at lower doses, resulting in neovascularization inhibition and ...

2016
Robert S. Kerbel Yuval Shaked

In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.

Journal: :Journal of pediatric hematology/oncology 2011
Giannoula Lakka Klement Barton A Kamen

In this issue of the journal, a prospective pediatric study by Fousseiny et al 1 evaluating a multidrug metronomic regimen in children with difficult-to-treat malignancies in Mali, is presented. It examines, for the first time in a prospective manner, the applicability of using established, off-patent agents in an alternative ‘‘metronomic’’ regimen. The authors, indirectly, make the case, that ...

2014
Genevieve M Weir Olga Hrytsenko Marianne M Stanford Neil L Berinstein Mohan Karkada Robert S Liwski Marc Mansour

In clinical trials, metronomic cyclophosphamide (CPA) is increasingly being combined with vaccines to reduce tumor-induced immune suppression. Previous strategies to modulate the immune system during vaccination have involved continuous administration of low dose chemotherapy, studies that have posed unique considerations for clinical trial design. Here, we evaluated metronomic CPA in combinati...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید